Skip to main content
    V

    Vertex Pharmaceuticals Inc (VRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $537.79
    -0.81 (-0.15%)

    Market Cap: $136.56B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vertex Pharmaceuticals Inc (VRTX) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Vertex Pharmaceuticals (VRTX) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Vertex Pharmaceuticals reported EPS of $4.21, below the $4.36 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    83%(33/40)
    Avg Surprise
    +11.12%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$4.19
    Range$3.71 - $5.32
    30 analysts
    Revenue Consensus
    $3.56B
    Range$3.35B - $3.77B
    28 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$4.68
    Range$4.18 - $5.28
    8 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$4.85-3.5%
    60d ago$4.63+1.0%
    30d ago$4.63+1.1%
    7d ago$4.78-2.1%
    Current$4.68
    Revenue Consensus
    $3.44B
    Range$3.10B - $3.66B
    6 analysts

    Next Report

    VRTX has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.7% below the $5.03 reported for the quarter ended Dec 31, 2025.

    VRTX Earnings Call

    The latest VRTX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, VRTX beat 33 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $3.44B, up 11.7% from $3.08B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$4.21$4.36$3.79 - $5.25-3.44%Miss-12.3%135 up, 1 downNov 2, 2026$3.44B
    Jun 30, 2026$4.20$4.15N/A+1.20%Beat-7.1%239 up, 9 downAug 3, 2026$3.33B
    Mar 31, 2026$4.47$4.31$3.67 - $4.86+3.81%Beat+10.1%242 up, 10 downMay 4, 2026$2.99B
    Dec 31, 2025$5.03$5.15$4.46 - $5.71-2.33%Miss+26.4%223 up, 4 downFeb 12, 2026$3.19B
    Sep 30, 2025$4.80$4.58$4.20 - $5.01+4.80%Beat+9.6%224 up, 7 downNov 3, 2025$3.08B
    Jun 30, 2025$4.52$4.25$3.92 - $4.63+6.35%BeatN/A231 up, 9 downAug 4, 2025$2.96B
    Mar 31, 2025$4.06$4.29$3.95 - $5.19-5.36%Miss-14.7%213 up, 6 downMay 5, 2025$2.77B
    Dec 31, 2024$3.98$4.02$3.41 - $4.85-0.99%Miss-5.2%254 up, 3 downFeb 10, 2025$2.91B
    Sep 30, 2024$4.38$4.13$3.77 - $4.90+6.05%Beat+7.4%224 up, 1 downNov 4, 2024$2.77B
    Jun 30, 2024-$12.83-$11.75N/A-9.19%Miss-429.8%101 up, 2 downAug 1, 2024$2.65B
    Mar 31, 2024$4.76$4.06$3.61 - $4.44+17.24%Beat+56.1%216 up, 1 downMay 6, 2024$2.69B
    Dec 31, 2023$4.20$4.09$3.83 - $4.43+2.69%Beat+11.7%217 up, 3 downFeb 5, 2024$2.52B
    Sep 30, 2023$4.08$3.97$3.34 - $4.39+2.77%Beat+1.7%223 up, 1 downNov 6, 2023$2.48B
    Jun 30, 2023$3.89$3.88$3.47 - $4.25+0.26%Beat+8.1%223 up, 1 downAug 1, 2023$2.49B
    Mar 31, 2023$3.05$3.00$2.63 - $3.67+1.67%Beat-13.4%202 up, 0 downMay 1, 2023$2.37B
    Dec 31, 2022$3.76$3.51$2.73 - $3.90+7.12%Beat+11.6%203 up, 1 downFeb 7, 2023$2.30B
    Sep 30, 2022$4.01$3.64$3.16 - $4.06+10.16%Beat+12.6%202 up, 2 downOct 27, 2022$2.33B
    Jun 30, 2022$3.60$3.50N/A+2.86%Beat+15.8%N/A1 up, 2 downAug 4, 2022$2.20B
    Mar 31, 2022$3.52$3.54$2.79 - $3.82-0.56%Miss+18.1%181 up, 0 downMay 5, 2022$2.10B
    Dec 31, 2021$3.37$3.29$3.03 - $3.70+2.43%Beat+34.3%191 up, 0 downJan 26, 2022$2.07B
    Sep 30, 2021$3.56$3.07$2.70 - $3.45+15.96%Beat+34.8%18N/ANov 2, 2021$1.98B
    Jun 30, 2021$3.11$2.38-$0.41 - $3.63+30.67%Beat+19.2%20N/AJul 29, 2021$1.79B
    Mar 31, 2021$2.98$2.69$2.04 - $3.06+10.78%Beat+16.4%19N/AApr 29, 2021$1.72B
    Dec 31, 2020$2.51$2.55$1.84 - $3.12-1.57%Miss+47.6%23N/AFeb 1, 2021$1.63B
    Sep 30, 2020$2.64$2.33$1.87 - $2.81+13.30%Beat+114.6%19N/AOct 29, 2020$1.54B
    Jun 30, 2020$2.61$2.08$1.51 - $2.52+25.48%Beat+107.1%21N/AJul 30, 2020$1.52B
    Mar 31, 2020$2.56$1.85$1.45 - $2.15+38.38%Beat+124.6%21N/AApr 29, 2020$1.52B
    Dec 31, 2019$1.70$1.22$1.02 - $1.37+39.34%Beat+30.8%21N/AJan 30, 2020$1.41B
    Sep 30, 2019$1.23$1.16$0.90 - $1.34+6.03%Beat+12.8%21N/AOct 30, 2019$949.83M
    Jun 30, 2019$1.26$1.07$0.98 - $1.24+17.76%Beat+34.0%20N/AJul 31, 2019$941.29M
    Mar 31, 2019$1.14$1.01$0.58 - $1.09+12.87%Beat+50.0%20N/AApr 30, 2019$858.43M
    Dec 31, 2018$1.30$1.06$0.68 - $1.26+22.64%Beat+113.1%22N/AFeb 5, 2019$87.59M
    Sep 30, 2018$1.09$1.01$0.88 - $1.13+7.92%Beat+105.7%22N/AOct 24, 2018$1.57B
    Jun 30, 2018$0.94$0.75$0.57 - $0.85+25.33%Beat+141.0%20N/AJul 25, 2018$752.16M
    Mar 31, 2018$0.76$0.63$0.44 - $0.77+20.63%Beat-42.9%22N/AApr 26, 2018$640.80M
    Dec 31, 2017$0.61$0.54$0.00 - $0.91+12.96%Beat+74.3%23N/AJan 31, 2018$651.63M
    Sep 30, 2017$0.53$0.37-$0.35 - $0.51+43.24%Beat+231.3%23N/AOct 25, 2017$578.16M
    Jun 30, 2017$0.39$0.36$0.22 - $0.41+8.33%Beat+62.5%19N/AJul 26, 2017$544.13M
    Mar 31, 2017$1.33$1.05N/A+26.67%Beat+1377.8%N/AN/AApr 27, 2017$714.72M
    Dec 31, 2016$0.35$0.29N/A+20.69%Beat+105.9%N/AN/AJan 25, 2017$458.71M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $18.41, up 6248.3% from the year before. It was $0.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$18.41+6248.3%
    Dec 31, 2024$0.29-98.1%
    Dec 31, 2023$15.22+2.2%
    Dec 31, 2022$14.89+14.4%
    Dec 31, 2021$13.02+26.2%
    Dec 31, 2020$10.32+93.6%
    Dec 31, 2019$5.33+30.3%
    Dec 31, 2018$4.09+43.0%
    Dec 31, 2017$2.86+240.5%
    Dec 31, 2016$0.84N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,46116
    2026Q2Jun 30, 20268,83117
    2026Q1Mar 31, 20269,15516
    2025Q4Dec 31, 20258,28917
    2025Q3Sep 30, 20258,17816
    2025Q2Jun 30, 20258,32216
    2025Q1Mar 31, 20258,67616
    2024Q4Dec 31, 20248,99317

    2026Q3 Earnings Call

    Opening remarks

    Susie Lisa Senior Vice President of Investor Relations Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our third quarter 2026 financial results conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Charles Wagner, Chief Operating Officer and Chief Financial Officer; and Duncan McKechnie, Chief Commercial Officer. Given Charles's January 1 transition to the COO role solely, please note that this is his last quarterly earnings call, and his successor, Jonathan Pool, our current SVP of Finance, will join us for our Q4 2026 call in February. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation, those regarding our marketed medicines for cystic fibrosis, sickle cell disease, beta thalassemia, moderate to severe acute pain, and acromegaly; our pipeline; the recently completed acquisition of Crinetics Pharmaceuticals and the expected benefits of that transaction; and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis. I will now turn the call over to Reshma.

    Reshma Kewalramani CEO and President Thanks, Susie. Good evening, all, and thank you for joining us on the call today. I am pleased to note that Vertex achieved another quarter of excellent commercial results and pipeline advancement. Third-quarter total revenue grew 12% year on year. Revenue growth was nicely balanced, coming from both the U.S. and international markets, from CF, and from our two more recently launched medicines, CASGEVY and JOURNAVX, as well as a contribution from PALSONIFY for the month of September following the close of the Crinetics acquisition. Rare endocrine is now our fourth commercial pillar. With the PDUFA date later this month for povetacicept in immunoglobulin A nephropathy, or IgAN, we plan to soon establish our fifth pillar in renal. Before turning to the R&D update, I want to acknowledge Charles's final—and 31st—earnings call as CFO. Charles's leadership, integrity, judgment, and intellectual rigor are unparalleled. He has deftly helped lead our transition from a CF-only company with $4 billion in revenue in 2019 to a company soon to be commercialized in five disease areas, with more than triple the revenue, with our guidance for over $13 billion in 2026.

    Frequently Asked Questions About VRTX

    When is Vertex Pharmaceuticals's next earnings date?

    Vertex Pharmaceuticals's next earnings report is expected for Feb 10, 2027.

    Did VRTX beat earnings estimates last quarter?

    No. Vertex Pharmaceuticals reported EPS of $4.21 for the quarter ended Sep 30, 2026, below the $4.36 estimate by 3.44%.

    What EPS do analysts expect from VRTX next quarter?

    The consensus EPS estimate for Vertex Pharmaceuticals for the quarter ending Dec 31, 2026 is $4.19 from 30 analysts, with estimates from $3.71 to $5.32.

    How often does VRTX beat earnings estimates?

    Vertex Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +0.51%.